Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2) - Xu, Jianming; Li, Yi; Fan, Qingxia; Shu, Yongqian; Yang, Lei; Cui, Tongjian; Gu, Kangsheng; Tao, Min; Wang, Xiuwen; Cui, Chengxu; Xu, Nong; Xiao, Juxiang; et al. (Nature communications, 2022)
Keywords: 631/67/1504/1477; 692/4028/67/1504/1477; Antibodies; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers; Biomarkers, Tumor - analysis; Cancer; Chemotherapy; Esophageal cancer; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - mortality; Esophageal Squamous Cell Carcinoma - drug therapy; Esophageal Squamous Cell Carcinoma - mortality; Esophagus; Female; Humanities and Social Sciences; Humans; Immune Checkpoint Inhibitors - therapeutic use; Irinotecan - therapeutic use; Lymphocytes T; Male; Medical prognosis; Metastases; Metastasis; Middle Aged; multidisciplinary; Paclitaxel - therapeutic use; Patients; PD-1 protein; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Progression-Free Survival; Receptors, Antigen, T-Cell - metabolism; Science; Science (multidisciplinary); Squamous cell carcinoma; T cell receptors; Tumors